Arena Pharmaceuticals, Inc. (ARNA)

[mick]

little red today after pr of patent. i don't think the street realizes the potential of this patent.

re;
That quote came from here:

What's even more Wow is what is in Red.

What exactly are they on to?

http://www.streetinsider.com/Litigation/Arena+Pharma+%28ARNA%29+Confirms+USPTO+Issued+Patent+for+APD371/9662739.html

Arena Pharma (ARNA) Confirms USPTO Issued Patent for APD371


Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2).

Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.

"Intellectual property protection is an important element of our clinical-stage pipeline," said Jack Lief, Arena's President and Chief Executive Officer. "This patent provides us further confidence that APD371 can be exclusive to Arena until at least 2030."

Arena owns patents and pending patent applications covering compositions of matter for APD371 and related compounds, as well as methods of treatment utilizing APD371 and related compounds.

Patent applications for APD371 have been filed in 23 jurisdictions, including the United States, Europe, Japan and China. The jurisdictions where patent applications have been filed are estimated to have accounted for more than 95% of global pharmaceutical sales in 2011.

About Chronic Pain

In the US alone, an estimated 100 million adults are burdened with chronic pain. Pain is the second leading cause of medically related work absenteeism, with greater than 50 million workdays lost each year.

The annual US economic cost related to chronic pain is estimated at $560-$635 billion. The global pain management therapeutics market was estimated at $29 billion in 2010.

About APD371

APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate Arena is exploring for several potential indications, including chronic pain.

This compound is designed to be highly selective to provide pain relief without psychotropic effects and without the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in animal models of pain.